Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
Type:
Grant
Filed:
September 26, 2008
Date of Patent:
September 9, 2014
Assignees:
U3 Pharma GmbH, Amgen Inc.
Inventors:
Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
Type:
Grant
Filed:
April 15, 2010
Date of Patent:
July 8, 2014
Assignees:
U3 Pharma GmbH, Amgen, Inc.
Inventors:
Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
Type:
Grant
Filed:
November 2, 2007
Date of Patent:
March 12, 2013
Assignee:
U3 Pharma GmbH
Inventors:
Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
Type:
Application
Filed:
May 11, 2010
Publication date:
May 10, 2012
Applicant:
U3 PHARMA GMBH
Inventors:
Peter Wirtz, Jens Ruhe, Takeshi Takilzawa, Tomoko Takayama
Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
Type:
Application
Filed:
November 12, 2010
Publication date:
September 22, 2011
Applicants:
U3 PHARMA GMBH, AMGEN
Inventors:
THORE HETTMANN, DANIEL J. FREEMAN, ROBERT RADINSKY
Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
Type:
Application
Filed:
September 26, 2008
Publication date:
May 12, 2011
Applicants:
AMGEN, INC., U3 PHARMA GMBH
Inventors:
Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
Type:
Application
Filed:
November 12, 2008
Publication date:
December 30, 2010
Applicant:
U3 PHARMA GMBH
Inventors:
Thore Hettmann, Jens Niewoehner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
Type:
Grant
Filed:
January 3, 2007
Date of Patent:
April 27, 2010
Assignees:
U3 Pharma GmbH, Amgen, Inc.
Inventors:
Mike Rothe, Martin Treder, Susanne Hartmann, Eric Borges, Larry L. Green
Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.